A Population Pharmacokinetic Model of High Dose Methotrexate in Adults with Cancer Identifies Baseline Albumin, Body Weight, and Time-dependent Creatinine as Predictors of Acute Kidney Injury

S. Howard, M. Ibarra,² R. Combs, and P. Schaiquevich

Insights from a pharmacometric analysis of HDMTX in adults with cancer: clinically relevant covariates for application in precision dosing

Manuel Ibarra,Ryan Combs,Zachary L. Taylor,Laura B. Ramsey,Torben Mikkelsen,Randal K. Buddington,Jesper Heldrup,Jason N. Barreto,Martin Guscott,Jennifer Lowe,Charles Hurmiz,Suresh Marada,Scott C. Howard,Paula Schaiquevich

Clinical Characteristics and Infection-Related Outcomes in Patients with Lymphoid Malignancies with or without Secondary Immunodeficiencies: Results from a Retrospective Multi-Database Study

Treatment Patterns of Patients With Soft Tissue Sarcoma Progressing to Third Line of Therapy

Vicki K. Wing MS, Philippe Martin MS, MBA, Aaron Galaznik MD, MBA, Li Shi MA, Emelly Rusli MPH, Lilia Bouzit MS, Chelsea Vigna MPH, Caleb Ball BS, and Rahul Jain PhD

Leveraging the integrated EHR for trial matching across a nationwide network

Timothy Joseph Yeatman, Mark Watson, Adam Chasse

Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations

Nina Shah ¹, Matthew Sussman ², Concetta Crivera ³, Satish Valluri ³, Jennifer Benner ⁴, Sundar Jagannath ⁵

Photo by Diane Serik

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

Sundar Jagannath, Yi Lin, Hartmut Goldschmidt, Donna Reece, Ajay Nooka, Alicia Senin, Paula Rodriguez-Otero, Ray Powles, Kosei Matsue, Nina Shah, Larry D. Anderson Jr, Matthew Streetly, Kimberly Wilson, Hoa Van Le, Arlene S. Swern, Amit Agarwal & David S. Siegel

Photo by Scott Graham

Racial Differences in Multiple Myeloma Survival and Treatment Using Pooled Clinical Trial and Real-World Electronic Medical Record Data

EmellyRusli*¹LihongDiaoMDMS*²CynthiaLiu*³⁴Mona AKelkarMBA*³⁵LisaEnsignPhDMS*²MarkWatsonMDPhD*⁶AaronGalaznikMDMBA¹

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

E. A. Klein, D. Richards, A. Cohn, M. Tummala, R. Lapham, D. Cosgrove, G. Chung, J. Clement, J. Gao, N. Hunkapiller, A. Jamshidi, K. N. Kurtzman, M. V. Seiden, C. Swanton & M. C. Liu

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland; The US Oncology Network, Tyler; The US Oncology Network, Denver; Mercy Clinic Cancer Center, Springfield; Spartanburg Regional Healthcare System, Spartanburg; Compass Oncology, Vancouver; The Christ Hospital Health Network, Cincinnati; Hartford HealthCare Cancer Institute, Hartford; GRAIL, Inc., Menlo Park; US Oncology Research, The Woodlands, USA; The Francis Crick Institute, London; University College London Cancer Institute, London, UK; Mayo Clinic, Rochester, USA

(Bold indicates GRN Partner Health Systems)

Evaluating progression-free survival in black and white women with triple-negative breast cancer in pooled clinical trials from a synthetic control database (SCD) and real-world electronic medical records (EMR).

Mark Layton Watson, Kevin Holcomb, Lisa Newman, Janna Andrews, Lisa Ensign, Aaron Galaznik, Bryant Fields, Sheila Diamond, Nicole Pollard